TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company“), is pleased to announce its financial and operational results for the third quarter ending September 30, 2025.
The Company remains in a strong financial position. A quarter-over-quarter comparison of Q3 2025 with Q2 2025 highlights a period of significant strengthening, with a 275% increase in shareholder equity, an 86% reduction in the debt-to-equity ratio, a 50% decrease in total liabilities, primarily due to the elimination of all liabilities associated with the previously issued convertible debentures, and an 8% reduction in General and Administrative expenses. Year to date, the Company has realized gains of US$572,000 from its digital asset portfolio, which is comprised mainly of Bitcoin. The company reaffirms its “no going concern” status, and management believes that existing capital resources are sufficient to maintain operations beyond March 2027.
Specifically, comparing Q3 2025 with Q2 2025, Quantum BioPharma has achieved:
A 50% reduction in total liabilities, decreasing from US$13.2M to US$6.6M;
A 275% increase in shareholder equity, increasing from US$2M up to US$7.5M , as a direct result of the above decrease in liabilities;
An 87% reduction in the Company’s debt-to-equity ratio, improving from a highly leveraged 6.47x to a strong and sustainable 0.89x;
A 40 percentage point increase in the equity to total assets ratio, from 13% to 53%, indicating that the Company’s assets are now predominantly financed by equity rather than debt; and
A significant improvement in liquidity, as evidenced by the current ratio increasing from 0.78x to 1.41x, further demonstrating the Company’s ability to cover its short-term obligations.
Strong Third Quarter Financials Sufficient to Maintain Operations Beyond March 2027
The Company continues to maintain a strong balance sheet while achieving cost control and reducing overhead and burn rate compared to prior quarters. Management believes there is sufficient cash on hand to sustain operations beyond March 2027.
Digital assets totaled US$5.2 million as of September 30, 2025, compared to US$0.8 million as of December 31, 2024.
All outstanding convertible debentures and their associated warrants have been fully exercised, eliminating the related liability from the Company’s balance sheet.
Total liabilities totaled US$6.6M as of September 31, 2025, compared to US$6.7M as of December 31, 2024.
General and Administrative expenses decreased by approximately US$210,000 in the third quarter of 2025, compared to the same quarter the previous year.
As of the date of this filing, the Company’s total realized gains on its digital asset portfolio amount to US$572,000.
Continued Progress with Multiple Sclerosis Drug, Lucid-21-302 (“Lucid-MS”) – Positive Toxicity Study, Joint PET Study with Acclaimed Mass General Scientists
The Company continues to advance clinical trials of its potential breakthrough multiple sclerosis drug, Lucid-21-302 (“Lucid-MS”), an oral-formulation drug that has shown, in pre-clinical animal studies, to stop nerve demyelination – the hallmark of multiple sclerosis.
Phase 1 oral toxicity studies of 3 and 6 months of Lucid-MS are complete and show no toxicity or side effects of the drug.
The oral formulation of Lucid-MS potentially offers an easier route of administration compared to current drugs requiring injection or infusion. The oral formulation of Lucid-MS will serve as the drug product for the company’s Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost due to multiple sclerosis (MS).
The Company, through its subsidiary, Huge Biopharma Australia Pty. Ltd., has signed an agreement with a leading contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS.
The first person with multiple sclerosis (MS) has been scanned in a joint study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in MS.
Quantum BioPharma has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the United States Food and Drug Administration (FDA).
Quantum Asset unbuzzd Continues to See Market Growth as Licensee Launches Capital Raise of up to $5 million USD in Preparation for Possible Initial Public Offering. No Equity Dilution for Quantum Shareholders
Unbuzzd Wellness Inc., the worldwide licensee of the Company’s asset, unbuzzd, a mix of supplements that has been clinically proven to both accelerate the metabolism of alcohol and reduce the symptoms of hangover, has:
Launched unbuzzd powder sticks in late 2024 in the United States; sales are increasing organically quarter over quarter. unbuzzd is available on amazon.com and unbuzzd.com;
Has hired MNP as auditors to prepare for a possible Initial Public Offering (IPO);
Has launched a Regulation D 506(c) offering to raise up to $5.0 million USD to support growth and distribution of unbuzzd, as well as fund a go-public event;
This offering does not dilute Quantum BioPharma’s shares in Unbuzzd Wellness.
Health Canada has …
Leave a Reply
You must be logged in to post a comment.